.jpg)
3 hours ago
3
Article content
Woburn, MA, July 21, 2026 (GLOBE NEWSWIRE) — Azurity Pharmaceuticals, a privately held specialty pharmaceutical company, today announced plans to commercialize D-PLEX100 upon approval in the United States and Canada for the prevention of abdominal colorectal surgical site infections (“SSIs”) in partnership with PolyPid Ltd. (“PolyPid”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, who will manufacture and supply D-PLEX100.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
SSIs remain among the most common healthcare-associated infections and may lead to prolonged hospital stays, higher readmission rates, increased healthcare costs, and worse patient outcomes.1,2 SSIs represent a significant clinical and economic burden across the U.S. health system:
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
- Patients who develop an SSI experience longer hospital stays, higher readmission rates, and higher medical costs than similar patients without an SSI.3
- Recent U.S. hospital analyses report that SSIs add approximately $30,689 in incremental hospital cost and 11.6 additional days of length of stay per affected admission.4
- In a large Veterans Affairs analysis, deep SSIs were associated with nearly 2x greater risk-adjusted costs versus comparable surgical admissions without SSI.3
- Among major healthcare-associated infections in the U.S., SSIs and C. difficile together account for approximately 79% of total attributable HAI costs.4
- SSIs are a leading cause of post-operative readmissions, including after colorectal surgery.5
Article content
D-PLEX100 is designed to provide local, prolonged and controlled antibacterial activity directly at the surgical site and is being evaluated for the prevention of abdominal colorectal SSIs. The U.S. Food and Drug Administration (“FDA”) acceptance of the D-PLEX100 New Drug Application (“NDA”) is expected in August 2026.
Article content
Article content
Azurity and PolyPid have jointly agreed to explore potential label expansion of D-PLEX₁₀₀ in the U.S. and Canada into additional SSI indications beyond abdominal colorectal, with Azurity providing funding for these additional clinical development programs. PolyPid will retain global commercial rights to D-PLEX100 outside of the U.S. and Canada, manufacturing rights worldwide, and full ownership of its PLEX platform, Kynatrix™ technology and associated pipeline assets.
Article content
“At Azurity, we believe meaningful innovation is measured by the difference a therapy makes in the realities of patient care,” said Ronald Scarboro, Chief Executive Officer of Azurity Pharmaceuticals. “D-PLEX100 is a differentiated therapy addressing an important unmet need, and we are excited to partner with PolyPid to help bring it to patients in the United States and Canada, if approved. Our commercial model is built to support specialized therapies like this— connecting the right treatment with the right healthcare professionals and patients through efficient, focused execution. Together, we look forward to expanding access to this important therapy while exploring opportunities to expand its impact and future clinical development.”
English (US)